ライフサイエンスコーパス: palbociclib

1 duced to ~0.3% with a 50-fold excess of cold palbociclib).

2 fulvestrant-palbociclib and 243 to letrozole-palbociclib).

3 y (4-hydroxytamoxifen) or CDK4/6 inhibitors (palbociclib).

4 pendent kinases 4 and 6 (CDK4/6) inhibition (Palbociclib).

5 ells were coincubated with a molar excess of palbociclib.

6 cer cells to the FDA-approved CDK4 inhibitor palbociclib.

7 ithout the cyclin-dependent kinase inhibitor palbociclib.

8 oading schedule and may be administered with palbociclib.

9 rther enhanced the in vivo tumor response to palbociclib.

10 the literature describing the development of palbociclib.

11 erapy and subsequent secondary resistance to palbociclib.

12 d responses to the CDK4/6-specific inhibitor palbociclib.

13 tients had stable disease after 12 months of palbociclib.

14 or to that of the CDK4/6 enzymatic inhibitor palbociclib.

15 clin D1 was inhibited pharmacologically with palbociclib.

16 e sensitivity of PIK3CA/AKT1 mutant cells to palbociclib.

17 X4 null xenografts being highly sensitive to palbociclib.

18 iDFS outcome in patients with LBC receiving palbociclib.

19 ciclib-based therapy when administered after palbociclib.

20 iple negative breast cancer (TNBC) models to palbociclib.

21 th as a single agent and in combination with palbociclib.

22 cNAcylation re-sensitizes resistant cells to palbociclib.

23 e resistant to fulvestrant +/- ribociclib or palbociclib.

24 anti-HER2/neu antibody and CDK4/6 inhibitor Palbociclib.

25 were insensitive to the CDK4-targeting drug palbociclib.

26 for CDK4/6 and a key driver of resistance to palbociclib.

27 n was associated with relative resistance to palbociclib.

28 fulvestrant and the CDK4 and CDK6 inhibitor palbociclib.

29 rated doses were ibrutinib 560 mg daily plus palbociclib 100 mg on days 1 to 21 of each 28-day cycle.

30 of 77.8 months, we recorded 225 deaths (108 palbociclib; 117 placebo) with a 6-year overall survival

31 juvant phase comprised the same regimen plus palbociclib 125 mg oral daily on days 1-21 of a 28-day c

32 inuous oral letrozole 2.5 mg daily plus oral palbociclib 125 mg, given once daily for 3 weeks followe

33 Palbociclib 125 mg/d was administered orally on a 21-day

34 e-based randomisation system to receive oral palbociclib (125 mg daily for 3 weeks followed by a week

35 eks on days 1 and 15 of a 28-day cycle) with palbociclib (125 mg orally once a day on days 1-21 of ea

36 were randomly assigned to receive 2 years of palbociclib (125 mg orally once daily, days 1-21 of a 28

37 ase 2 study demonstrated that treatment with palbociclib (200 mg daily for 14 days every 21 days) res

38 When fulvestrant is combined with palbociclib (a cyclin-dependent kinase 4/6 inhibitor), a

39 We previously reported that palbociclib (a selective CDK4/6 inhibitor) given with ce

40 Here, we show that palbociclib, a CDK4/6 inhibitor, and paclitaxel, a micro

41 amming in colorectal cancer cells exposed to Palbociclib, a CDKi selectively targeting CDK4/6, or Tel

42 Palbociclib, a specific CDK4/6 inhibitor, rapidly induce

43 cells continues to divide in the presence of palbociclib-a phenomenon we refer to as fractional resis

44 developed, including three small molecules (palbociclib, abemaciclib and ribociclib) that are curren

45 ole (group A), fulvestrant (groups B-D), and palbociclib (all groups) were administered at standard d

46 nvestigated the efficacy of CDK4/6 inhibitor palbociclib alone or in combination with ruxolitinib in

47 Combined Rt3D-palbociclib also increases innate immune activation and

48 By indirectly suppressing PRMT5 activity, palbociclib alters the pre-mRNA splicing of MDM4, a nega

49 correlated with liver cancer sensitivity to palbociclib, an FDA-approved CDK4 inhibitor, which was e

50 g ex vivo-treated p21-deficient T cells with palbociclib, an inhibitor of cyclin-dependent kinase 4/6

51 Furthermore, palbociclib, an oral CDK4/6 inhibitor, significantly inc

52 articipants, 103 (86.5%) previously received palbociclib and 14 participants received ribociclib (11.

53 e randomly assigned, 347 to fulvestrant plus palbociclib and 174 to fulvestrant plus placebo.

54 [3.7%]) were randomized (243 to fulvestrant-palbociclib and 243 to letrozole-palbociclib).

55 Combined treatment of palbociclib and 7rh further induced cell cycle arrest in

56 p, phase 2 trial to evaluate the activity of palbociclib and cetuximab in platinum-resistant (group 1

57 atients achieving an objective response with palbociclib and cetuximab in recurrent or metastatic HNS

58 or cetuximab-resistant HPV-unrelated HNSCC, palbociclib and cetuximab results in promising activity

59 acquired resistance to the CDK4/6 inhibitor palbociclib and demonstrate that the activity of PRMT5,

60 ined with ATP-competitive inhibitors such as palbociclib and dinaciclib is presented, followed by a c

61 Gedatolisib plus palbociclib and endocrine therapy showed a promising obj

62 n of palbociclib in patients still receiving palbociclib and endocrine therapy.

63 ulation of Cyclin D2 and Cyclin E2 caused by palbociclib and enhances the suppression of phospho-Rb,

64 Inavolisib plus palbociclib and ET demonstrated a manageable safety prof

65 clinical relevance, combined treatment with palbociclib and FLT3 inhibitors results in synergistic c

66 , treatment with AZD4573 in combination with palbociclib and fulvestrant resulted in tumor regression

67 e combination of the CDK4 and CDK6 inhibitor palbociclib and fulvestrant was associated with signific

68 b, a HER2-targeted bispecific antibody, plus palbociclib and fulvestrant, in heavily pretreated patie

69 inhibition of GPX4 increases sensitivity to palbociclib and giredestrant, and their combination, in

70 Favorable results with palbociclib and its recent U.S. Food and Drug Administra

71 cell-cycle and OCT2-targeting activities of palbociclib and LEE011, combined with their potential fo

72 rvival rate (79.4% vs 77.1%) for fulvestrant-palbociclib and letrozole-palbociclib, respectively.

73 bitor combinatorial effect is not limited to palbociclib and MSC2504877 and is elicited with other CD

74 educed toxicity of CDK4/6 inhibitors such as palbociclib and multi-CDK inhibitors such as dinaciclib

75 Both palbociclib and ribociclib have been approved in combina

76 More myelotoxicity is observed with palbociclib and ribociclib, but more gastrointestinal to

77 nvestigated the potential of CDK inhibitors, Palbociclib and RO-3306, on neuroblastoma cell different

78 Combined treatment of palbociclib and ruxolitinib resulted in normalization of

79 ings demonstrate the sensitivity of DSRCT to palbociclib and support immediate clinical investigation

80 Gedatolisib, palbociclib, and endocrine therapy induced an objective

81 ncer cells activate autophagy in response to palbociclib, and that the combination of autophagy and C

82 e used the PubMed search terms "PD0332991," "palbociclib," and "CDK4/6 inhibitor" to find all publish

83 GSK2334470 in combination with ribociclib or palbociclib, another CDK4/6 inhibitor, synergistically i

84 tivation, suggesting that inhibitors such as palbociclib are likely to provide therapeutic benefit in

85 r overall survival (OS) rate of 82.4% in the palbociclib arm versus 80.3% in the placebo arm (hazard

86 ial, 302 patients had tumor tissue analyzed (palbociclib arm, 194 patients; placebo arm, 108 patients

87 clin E1 (CCNE1) mRNA expression (median PFS: palbociclib arm, 7.6 v 14.1 months; placebo arm, 4.0 v 4

88 Taken together, these results support palbociclib as a promising therapeutic for treatment of

89 Patients received oral palbociclib at 125 mg daily for 21 days in 28-day cycles

90 It is important to understand whether palbociclib at a new dose and schedule-125 mg daily for

91 terference of endothelial QKI expression and palbociclib blockade of CCND1 function potently inhibite

92 Specific inhibition of CDK4 activity by palbociclib blocked DREAM complex disassembly during cel

93 on inhibition caused by the CDK4/6 inhibitor palbociclib, but not to inhibitors of S phase or mitosis

94 duced by the oral, specific CDK4/6 inhibitor palbociclib can overcome ibrutinib resistance in primary

95 , AKT3-vandetanib, BCR-imatinib, CDK1 and 20-palbociclib, CASP1-imexon, and FGFR3-pazopanib.

96 ns showed that the clinical CDK4/6 inhibitor palbociclib, causes enhanced sensitivity to MSC2504877.

97 ostat (pan-histone deacetylase inhibitor) or palbociclib (CDK4/6 inhibitor) or ABT-199 (BCL2 antagoni

98 ak1), AZD1208 (Pim), dactolisib (PI3K/mTOR), palbociclib (Cdk4/6), and venetoclax (Bcl-2).

99 ed taselisib (targeting PIK3CA alterations), palbociclib (cell cycle gene alterations), AZD4547 (FGFR

100 the reovirus type III Dearing strain (Rt3D)-palbociclib combination augments oncolytic virus-induced

101 mice reversed the effects of the MSC2504877/palbociclib combination, suggesting one molecular route

102 his today is the use of the CDK4/6 inhibitor palbociclib combined with aromatase inhibitors for the t

103 AI and in baseline plasma from the PALOMA3 (Palbociclib Combined With Fulvestrant in Hormone Recepto

104 positive/HER2-negative MBC who progressed on palbociclib-containing regimens can exhibit a meaningful

105 Specific CDK inhibition by dinaciclib and palbociclib decreases PASMC proliferation via cell cycle

106 at, when targeted using the CDK4/6 inhibitor palbociclib, defines overlap and divergence of adjuvant

107 Although fulvestrant-palbociclib demonstrated significant antitumor activity,

108 eatment combinations including Afuresertib + Palbociclib, Dinaciclib + Trametinib, Afatinib + Oxalipl

109 Palbociclib efficacy was lower in patients with high ver

110 o currently FDA approved drugs, afatinib and palbociclib (EGFR and CDK4/6 inhibitors, respectively) d

111 The addition of MSC2504877 to palbociclib enhances G(1) cell cycle arrest and cellular

112 palbociclib plus letrozole to 14 weeks (B); palbociclib for 2 weeks, then palbociclib plus letrozole

113 al trials of the CDK4/6 inhibitor (CDK4i/6i) palbociclib for ALM; however, median progression free su

114 T02871791) of exemestane plus everolimus and palbociclib for CDK4/6i-resistant metastatic breast canc

115 DKi dinaciclib as a promising alternative to palbociclib for the suppression of MB cells proliferatio

116 support immediate clinical investigation of palbociclib for treating this aggressive pediatric cance

117 While CDK4/6 inhibitors are FDA approved (palbociclib) for treating advanced estrogen receptor-pos

118 fulvestrant versus 7.3 months for placebo + palbociclib + fulvestrant (hazard ratio [HR], 0.43 [95%

119 a median PFS of 15.0 months for inavolisib + palbociclib + fulvestrant versus 7.3 months for placebo

120 ib (at an oral dose of 9 mg once daily) plus palbociclib-fulvestrant (inavolisib group) with placebo

121 estrant (inavolisib group) with placebo plus palbociclib-fulvestrant (placebo group) in patients with

122 Inavolisib plus palbociclib-fulvestrant has shown synergistic activity i

123 or metastatic breast cancer, inavolisib plus palbociclib-fulvestrant led to significantly longer prog

124 progression-free survival than placebo plus palbociclib-fulvestrant, with a greater incidence of tox

125 Addition of the FGFR TKI erdafitinib to palbociclib/fulvestrant induced complete responses of FG

126 mbines effectively with the CDK4/6 inhibitor palbociclib, further prolonging survival in vivo.

127 incorporated sites of action of four drugs (palbociclib, gemcitabine, paclitaxel and actinomycin D)

128 (95% CI, 25.8-35.9 months) in the letrozole-palbociclib group (hazard ratio, 1.13; 95% CI, 0.89-1.45

129 0 years [IQR 57.0-68.5]) or anastrozole plus palbociclib group (n=109; median age 62.0 [57.0-67.0] ye

130 d randomly assigned to the giredestrant plus palbociclib group (n=112; median age 62.0 years [IQR 57.

131 ts had occurred (145 in the fulvestrant plus palbociclib group and 114 in the fulvestrant plus placeb

132 atients (13%) of 345 in the fulvestrant plus palbociclib group and 30 (17%) of 172 patients in the fu

133 73%) of 345 patients in the fulvestrant plus palbociclib group and 38 (22%) of 172 patients in the fu

134 hs (95% CI 9.2-11.0) in the fulvestrant plus palbociclib group and 4.6 months (3.5-5.6) in the fulves

135 utropenia (223 [65%] in the fulvestrant plus palbociclib group and one [1%] in the fulvestrant plus p

136 ia (29 [26%] of 112 in the giredestrant plus palbociclib group vs 29 [27%] of 109 in the anastrozole

137 95% CI, 24.2-33.1 months) in the fulvestrant-palbociclib group vs 32.8 months (95% CI, 25.8-35.9 mont

138 p vs 29 [27%] of 109 in the anastrozole plus palbociclib group) and decreased neutrophil count (17 [1

139 versus 25.8% (95% CI 11.9% to 44.6%) in the palbociclib group.

140 CDK4/6 inhibition with palbociclib had clinical activity in PMC characterized b

141 As palbociclib has been approved by the FDA for the treatme

142 rly- and late-phase clinical trials in which palbociclib has been investigated in a broad array of tu

143 le cancers and the CDK4/6 specific inhibitor palbociclib has been pre-clinically identified as an eff

144 toward better survival outcomes in favor of palbociclib (hazard ratio 0.45, 95% CI 0.19-1.07, P = 0.

145 ts displayed a durable antitumor response to palbociclib; however, over the course of treatment, few

146 Fulvestrant plus palbociclib improved PFS compared with fulvestrant plus

147 Clinical evaluation of binimetinib and palbociclib in a safety lead-in confirmed safety and pro

148 optimally forestalls acquired resistance to Palbociclib in cancer cells.

149 Palbociclib in combination with anti-hormonal therapy br

150 er, coadministration of the CDK4/6 inhibitor palbociclib in combination with H3B-6527 could effective

151 e aimed to assess the safety and efficacy of palbociclib in combination with letrozole as first-line

152 k suggests a new therapeutic opportunity for palbociclib in lung and other cancers currently treated

153 targeted agents such as the CDK4/6 inhibitor palbociclib in others, whereas the importance of BCR sig

154 ing committee recommended discontinuation of palbociclib in patients still receiving palbociclib and

155 ee survival with this regimen over letrozole-palbociclib in patients with endocrine-sensitive, hormon

156 ished in a clinical trial of binimetinib and palbociclib in patients with metastatic colorectal cance

157 lvestrant plus placebo with fulvestrant plus palbociclib in patients with progression after receiving

158 han treatment with the dual CDK4/6 inhibitor palbociclib in suppressing Ph+ ALL in mice, suggesting t

159 ated with poor antiproliferative activity of palbociclib in the POP trial (P = .005).

160 nhibitor GSK3326595 enhances the efficacy of palbociclib in treating naive and resistant models and a

161 improved biologic response to the CDK4/6(i) palbociclib, in combination with an aromatase inhibitor

162 As such, while Palbociclib induced reduced tumor growth in vivo, and Te

163 encing or the clinically relevant inhibitor, Palbociclib, induced growth inhibition both in vitro and

164 translocation to nuclei, where it suppresses palbociclib-induced senescence.

165 inistration-approved CDK4/6 kinase inhibitor palbociclib induces apoptosis of FLT3-ITD leukemic cells

166 demonstrate that the combination of JQ1 and palbociclib induces cell division errors, which can incr

167 Furthermore, we have established that palbociclib inhibition of the PRMT5-MDM4 axis is essenti

168 The selective CDK4 and CDK6 inhibitor palbociclib inhibits growth and induces senescence in li

169 Palbociclib instead primarily targeted monomeric CDK4 an

170 Acquired resistance to fulvestrant and palbociclib is a new challenge to treatment of estrogen

171 Palbociclib is a potent and specific oral cyclin-depende

172 Palbociclib is well tolerated and has therapeutic potent

173 e inhibition by the clinically-approved drug Palbociclib leads to marked tumor burden decrease in DSR

174 re randomly assigned (74 paclitaxel + HP, 73 palbociclib + letrozole + HP) and 145 constituted the tr

175 lockade with a chemotherapy-free backbone of palbociclib + letrozole yields pCR rates similar to pacl

176 -dependent signaling by the CDK4/6 inhibitor Palbociclib markedly slowed disease progression in mice

177 sults demonstrate that inhibition of CDKs by palbociclib may be a therapeutic strategy in PAH.

178 sticity, which enables tumor models to evade palbociclib-mediated activation of RB, could be targeted

179 y, endothelial cell late G1 state induced by palbociclib modulates the expression of genes regulating

180 Here, we show that the CDK4/6 inhibitor palbociclib not only inhibits proliferation but induces

181 Resistance to palbociclib occurred as a result of tumour cell re-wirin

182 iation of gene expression with the effect of palbociclib on progression-free survival (PFS) was evalu

183 of camizestrant in combination with CDK4/6i (palbociclib or abemaciclib) in CDK4/6-naive and -resista

184 Mechanistically, treatment with palbociclib or depletion of CDK6 inhibited Aurora kinase

185 All patients received palbociclib orally (125 mg/day, on days 1-21) and intrav

186 doses of ribociclib (R), abemaciclib (A), or palbociclib (P) over 8 months (0-600 nM).

187 Interestingly, a CDK4/6 inhibitor, palbociclib (P), also induced autophagy and overrode c-M

188 e loading to co-encapsulate CDK4/6 inhibitor palbociclib (PAL) and an autophagy inhibitor hydroxychlo

189 CDK4/6 pathway by small-molecule inhibitors palbociclib (PD-0332991) and ribociclib (LEE011) resulte

190 Palbociclib (PD-0332991) is an oral, small-molecule inhi

191 Palbociclib (PD0332991) is a newly developed drug that r

192 0 patients were randomly assigned to receive palbociclib plus endocrine therapy (n=2883) or endocrine

193 16.9-29.2), 170 of 2883 patients assigned to palbociclib plus endocrine therapy and 181 of 2877 assig

194 ee survival was 88.2% (95% CI 85.2-90.6) for palbociclib plus endocrine therapy and 88.5% (85.8-90.7)

195 in 253 of 2,884 (8.8%) patients who received palbociclib plus endocrine therapy and in 263 of 2,877 (

196 ent-emergent adverse events were higher with palbociclib plus ET (47.4% v 10.0%), without new safety

197 ents in the ET-alone arm (65.7%) than in the palbociclib plus ET arm (33.0%) received cyclin-dependen

198 Conversely, more patients in the palbociclib plus ET arm (52.5%) than in the ET-alone arm

199 36 and 62 patients were randomly assigned to palbociclib plus ET or ET alone, respectively.

200 PFS was 4.9 months (95% CI, 3.6 to 6.1) with palbociclib plus ET versus 3.6 months (95% CI, 2.5 to 4.

201 cohort 1, patients were randomised 1 : 1 to palbociclib plus exemestane or capecitabine.

202 anastrozole or letrozole (0.42; 0.23-0.76), palbociclib plus fulvestrant (0.37; 0.23-0.59), ribocicl

203 which patients were randomised 1 : 1 between palbociclib plus fulvestrant and capecitabine.

204 dosing, safety, and preliminary activity of palbociclib plus ibrutinib in patients with previously t

205 patients had grade 3 or greater toxicity on palbociclib plus letrozole (49.8% v 17.0%; P < .001) mai

206 Palbociclib plus letrozole (HR 0.42; 95% credible interv

207 More patients on palbociclib plus letrozole achieved complete cell-cycle

208 12, we randomly assigned 165 patients, 84 to palbociclib plus letrozole and 81 to letrozole alone.

209 onse was not significantly different between palbociclib plus letrozole and letrozole groups ( P = .2

210 al that evaluated the effects of combination palbociclib plus letrozole as neoadjuvant therapy.

211 an log-fold change in Ki-67 was greater with palbociclib plus letrozole compared with letrozole (-4.1

212 lbociclib plus letrozole to 14 weeks (C); or palbociclib plus letrozole for 14 weeks.

213 herapy regimen was significantly better than palbociclib plus letrozole for progression-free survival

214 and 26.1 months (11.2-not estimable) for the palbociclib plus letrozole group (HR 0.299, 0.156-0.572;

215 le group and 20.2 months (13.8-27.5) for the palbociclib plus letrozole group (HR 0.488, 95% CI 0.319

216 le group and 18.1 months (13.1-27.5) for the palbociclib plus letrozole group (HR 0.508, 0.303-0.853;

217 ow-up 29.6 months [95% CI 27.9-36.0] for the palbociclib plus letrozole group and 27.9 months [25.5-3

218 ion-free survival events had occurred in the palbociclib plus letrozole group and 59 in the letrozole

219 11 (13%) patients in the palbociclib plus letrozole group and two (2%) in the let

220 s reported in 45 (54%) of 83 patients in the palbociclib plus letrozole group versus one (1%) of 77 p

221 hat occurred in more than one patient in the palbociclib plus letrozole group were pulmonary embolism

222 Coprimary end points for letrozole versus palbociclib plus letrozole groups (A v B + C + D) were c

223 t regimen that was significantly better than palbociclib plus letrozole in terms of the proportion of

224 or 14 weeks (A); letrozole for 2 weeks, then palbociclib plus letrozole to 14 weeks (B); palbociclib

225 14 weeks (B); palbociclib for 2 weeks, then palbociclib plus letrozole to 14 weeks (C); or palbocicl

226 oly (ADP-ribose) polymerase was greater with palbociclib plus letrozole versus letrozole (-0.80 v -0.

227 eatments were compared to anastrozole and to palbociclib plus letrozole.

228 nced cytotoxicity and anti-tumor effect with palbociclib plus taxanes at clinically achievable doses

229 Further, CDK inhibition with palbociclib promoted autophagy-dependent degradation of

230 n D-CDK4/6-RB axis that can be targeted with palbociclib, providing a targeted therapeutic strategy f

231 The CDK4/6 inhibitor palbociclib reduces tumor growth by decreasing retinobla

232 The most common grade 3-4 palbociclib-related adverse event was neutropenia (in 21

233 ance to CDK4/6 inhibitors (CDK4/6i), such as palbociclib, remains a substantial challenge in clinical

234 ance to CDK4/6 inhibitors (CDK4/6i), such as palbociclib, remains a substantial hurdle in clinical pr

235 udies shed light on the mechanism regulating palbociclib resistance and present clinical evidence for

236 PDGF-BB axis by specific inhibitors overcame palbociclib resistance both in vitro and in vivo.

237 ding different RB-positive PDX with acquired palbociclib resistance.

238 addition, in two independent endocrine- and palbociclib-resistance patient-derived xenografts, treat

239 In vitro, endocrine and palbociclib resistant cells show increased OXPHOS depend

240 d and evaluated ribociclib, abemaciclib, and palbociclib-resistant BCs.

241 tion of MITF in tumors from patients who are palbociclib-resistant or undergoing palbociclib treatmen

242 cells was confirmed in endocrine-resistant, palbociclib-resistant, and ESR1 mutant cell lines.

243 %) for fulvestrant-palbociclib and letrozole-palbociclib, respectively.

244 nocrotaline and Su5416/hypoxia treated rats) palbociclib reverses the elevated right ventricular syst

245 ependent kinase 4 and 6 inhibitors (CDK4/6i: palbociclib, ribociclib, abemaciclib) and endocrine ther

246 bursement decisions of the CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib and estimated t

247 Palbociclib, ribociclib, and abemaciclib represent a new

248 , including compounds that target CDK4/CDK6 (palbociclib, ribociclib, and abemaciclib), aurora kinase

249 Three different oral CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib, have significa

250 In vivo, 7rh significantly enhanced palbociclib's antitumor efficacy.

251 M complex in both normal cells as well as in palbociclib-sensitive cancer cell lines.

252 ating HP breast cancers, with neratinib plus palbociclib showing a statistically significant reductio

253 The effects are not mirrored by palbociclib, showing that the functions of CDK6 in MPN p

254 In vivo palbociclib significantly inhibits tumor growth in mouse

255 Importantly, lapatinib and palbociclib strictly block de novo synthesis of DNA, mos

256 rafenib-resistant tumors remain sensitive to palbociclib, suggesting that initial treatment with vemu

257 to neoadjuvant aromatase inhibitor (AI) plus palbociclib than to neoadjuvant AI alone, as indicated b

258 in-dependent kinase 4/6 inhibitor, PD0332991/palbociclib, that mimics the endogenous effect of p16(IN

259 III PALLAS trial, the addition of 2 years of palbociclib to adjuvant endocrine therapy (ET) did not i

260 im analysis, addition of 2 years of adjuvant palbociclib to adjuvant endocrine therapy did not improv

261 f patients most suitable for the addition of palbociclib to endocrine therapy after tumour recurrence

262 uvant setting, the potential value of adding palbociclib to endocrine therapy for hormone receptor-po

263 Addition of palbociclib to endocrine therapy improves progression-fr

264 Addition of palbociclib to fulvestrant demonstrated efficacy in all

265 associated with the effectiveness of adding palbociclib to fulvestrant.

266 r small-molecule inhibitors, synergized with palbociclib to induce senescence in NSCLC cells and tumo

267 tive breast cancer-bearing mice treated with palbociclib to induce senescence.

268 The addition of palbociclib to letrozole in this phase 2 study significa

269 Adding palbociclib to letrozole significantly enhanced the supp

270 f cyclin-dependent kinase inhibitors such as palbociclib to reduce T-cell exhaustion for future treat

271 Loss of the ability of palbociclib to regulate the PRMT5-MDM4 axis leads to res

272 f the PALLAS trial, the addition of adjuvant palbociclib to standard endocrine therapy did not improv

273 Nanoparticle encapsulation reduced palbociclib toxicity, enabled parenteral administration,

274 cence with the combination of trametinib and palbociclib (TP) yields several tumorigenic and prometas

275 In the newly validated system, palbociclib treatment efficiently inhibited tumor cell g

276 of cyclin D1 amplification in the PDXC line, palbociclib treatment had no effect on cell proliferatio

277 driven BC, including patients progressing on palbociclib treatment.

278 protein JARID2, rendered cells resistant to palbociclib treatment.

279 who are palbociclib-resistant or undergoing palbociclib treatment.

280 t cells were significantly more resistant to palbociclib treatment.

281 More patients completed palbociclib versus paclitaxel (94.4% versus 79.5%).

282 No significant improvement was noted for palbociclib versus placebo for iDFS, distant disease-fre

283 The combination of MSC2504877 and palbociclib was also effective in suppressing the cellul

284 tients with advanced WD/DDLS, treatment with palbociclib was associated with a favorable PFS and occa

285 Fulvestrant plus palbociclib was associated with significant and consiste

286 Palbociclib was efficacious in both luminal A and lumina

287 tegy A was 31.6 QALMs versus strategy C when palbociclib was included in strategy C; similarly, strat

288 No significant iDFS benefit of palbociclib was observed in any subgroup, including anal

289 For example, letrozole plus palbociclib was ranked first and letrozole plus ribocicl

290 Nonradioactive palbociclib was used as a blocking agent to investigate

291 rgetable and the selective CDK4/6 inhibitor, palbociclib, was recently FDA approved for the treatment

292 underlying molecular/cellular mechanisms for palbociclib were explored in squamous cell lung cancer (

293 Likewise, initial responses to Palbociclib were followed by signs of adaptation and res

294 ents treated with an aromatase inhibitor and palbociclib were screened every 2 months for activating

295 eriod, 1616 patients (87%) were treated with palbociclib, whereas 157 patients (7%) received ribocicl

296 Similarly, combination treatment of palbociclib with a MEK inhibitor in pancreatic cancer PD

297 Additional combinations of palbociclib with endocrine therapy, chemotherapy, and ta

298 itial treatment with vemurafenib followed by palbociclib with or without mTOR inhibitors might provid

299 esistance, which were prevented by combining Palbociclib with Telaglenastat.

300 Importantly, combining palbociclib with the PRMT5 inhibitor GSK3326595 enhances